



Year-end Report January - December 2021

October – December 2021

- **Net sales** rose by 112% to SEK 42,060 (19,850) thousand. About SEK 20 million relates to licensing agreements with Selecta Bioscience. Growth is 108%, adjusted for currency effects.
- **Gross profit** rose by 97% to SEK 39,024 (19,761) thousand.
- **Operating profit before depreciation and amortization (EBITDA)** totaled SEK 23,361 (6,196) thousand.
- **Operating profit** jumped SEK 17,291 thousand and totaled SEK 21,895 (4,604) thousand.
- **Comprehensive income for the period** improved by SEK 16,828 thousand and totaled SEK 23,175 (6,347) thousand.
- **Comprehensive income per share** totaled SEK 0.35 (0.10).
- **Cash flow from operating activities** was SEK 37,368 (-672) thousand.
- **Cash and cash equivalents at the end of the period** totaled SEK 81,315 (44,118) thousand.
- Magnus Långberg has been hired as the new CFO for the group; his most recent position was at Hemocue AB. Before that he worked at companies such as QPharma and BD Medical.
- Genovis has entered into an exclusive licensing agreement with Selecta Bioscience Inc. to develop and promote a novel patent pending antibody-cleaving enzyme, Xork™, as a potential pretreatment prior to the administration of gene therapy and for autoimmune diseases. Under the terms of the multi-year agreement, Genovis will receive USD 6 million in advance payment and early milestone payments, and is entitled to up to USD 598 million in development, regulatory and commercial milestone payments. Genovis will also receive double-digit royalties on sales of Xork.

January – December 2021

- **Net sales** rose by 52% to SEK 93,018 (61,030) thousand. Growth is 56%, adjusted for currency effects. About SEK 20 million relates to licensing agreements with Selecta Bioscience.
- **Gross profit** improved by 44% to SEK 85,600 (59,370) thousand.
- **Operating profit before depreciation and amortization (EBITDA)** totaled SEK 30,314 (8,573) thousand.
- **Operating profit** improved by SEK 21,403 thousand and totaled SEK 24,543 (3,140) thousand.
- **Comprehensive income for the period** improved by SEK 24,856 thousand and totaled SEK 26,828 (1,973) thousand.
- **Comprehensive income per share**, basic and diluted, totaled SEK 0.41 (0.03).
- **Cash flow from operating activities** was SEK 45,411 (3,755) thousand.

(SEK 000s)	Oct.-Dec.		Jan. – Dec.	
	2021	2020	2021	2020
Net sales	42,060	19,850	93,018	61,030
Gross profit	39,024	19,761	85,600	59,370
Operating profit (EBIT)	21,895	4,604	24,543	3,140
Comprehensive income for the period	23,175	6,347	26,828	1,973
Cash flow from operating activities	37,368	-672	45,411	3,755
Cash and cash equivalents at end of period	81,315	44,118	81,315	44,118
Earnings per share* (SEK)	0.35	0.13	0.41	0.10

* Earnings per share is calculated by dividing comprehensive income by the weighted average number of shares during the year. There is no dilution effect.

Comments from Fredrik Olsson, Chief Executive Officer

We show strong growth for the fourth quarter, driven in part by revenue related to the license business in Gene Therapy, as well as from a recovery in our core business in Analytics, where we saw higher customer activity in all geographic markets.

Revenue from Gene Therapy increased almost six times compared with the corresponding quarter last year and totaled about SEK 20 million, mainly attributable to license revenue from our collaboration agreement with Selecta Bioscience.

We are also pleased to see that enzyme sales in Analytics grew by 35%, reflecting the improved market situation we experienced during much of the quarter as a result of eased restrictions, with customers able to return to work in laboratories to a greater extent.

Sales in our antibody business showed a weaker trend compared with the corresponding period last year, mainly because they relate to service operations with lengthy projects, where shifts in revenue between individual quarters are not uncommon. Several development programs are currently underway for products that complement the enzyme business in gene therapy, where the first products, which were launched in 2021, were well received by our customers.

We launched two new products during the fourth quarter, which means that we launched an impressive six products in the enzyme business in 2021. Both products were well received, which confirms our ability to pay close attention to the market in order to guide our product development and create value for our customers. Continuing to broaden the product portfolio is one of our key strategic goals for both current and future application areas for our enzyme technology. We have also expanded our antibody offering with products for research in Alzheimer's Disease and will add additional products during 2022.

Despite periods of challenges in different parts of the business in 2021, we can once again report yet another year of strong growth and it is particularly rewarding to note that we achieved our best earnings to date. Our focus on customers and on new applications for our enzyme technology is the basis of our success. In the short term, uncertainties persist regarding Covid-19 developments, but in the longer term, Genovis' growth opportunities remain intact. We have built up a good cash base, which enables us to be enterprising and invest in Genovis' continued growth journey.

Our successes in 2021 lay an excellent foundation for expansion as a result of license revenue and a strong expansion of the product offering through six launched products. The final quarter of the year was therefore characterized by additional bold initiatives through the expansion of our organization. We are now implementing several strategic initiatives within both the sales and business development organizations. In addition to a new vice president of global sales and marketing, at the beginning of 2022 the sales organization was strengthened with sales representatives in local markets to increase our opportunities to be even closer to our customers. In Europe, we began with a presence in the UK and we intend to expand to more geographic markets during the year. In Asia, beginning in January, for the first time we have our own sales staff in the strategically important Shanghai region in China. We also added resources for our strategic efforts in business development in order to take advantage of more opportunities in new application areas, licensing and potential acquisition opportunities in the future. At the beginning of 2022 we strengthened the commercial organization in San Diego with the aim of expanding our products and services for the antibody business.

I would like to close by thanking the Board of Directors and shareholders for their support and commitment over the past year. I would also like to warmly thank my colleagues at Genovis, who have done an amazing job of handling a challenging year with great dedication, for which reason I look forward with confidence to 2022.



Genovis Group in brief

Genovis will apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future.



The Group's enzymes and antibodies are in a market that covers the entire life science and biotech supply industries. The Company markets a total of 19 enzymes in different product formats under the common SmartEnzymes™ brand. Until 2020, the subsidiary Genovis Inc. only served as distributor for Genovis AB's products with responsibility for the North American market. In April 2020, Genovis AB acquired all shares in QED Biosciences Inc., which immediately

merged with Genovis Inc. In addition to marketing and sales of SmartEnzymes™, Genovis Inc.'s business now also includes sales and production of antibodies for the research and diagnostics market.

The Parent Company in Lund handles sales and marketing in the European market, including development, application and support, as well as production of SmartEnzymes™. In Asia, Genovis works with both direct sales and distributors who are familiar with the local market.


Central functions are governed from Genovis AB, which has a business model with a long-term and sustainable focus based on two primary strategies that together are the drivers of the Company's success:

- Continue to launch unique new products, thereby expanding the customer offering for continued good growth.
- Deliberately work to encourage customers to use Genovis products all the way to the release and approval of new biological drugs.

The Group will have a creative focus and develop unique new products that have a high value for the customer. New products are mainly aimed at customers who work in the discovery phase, preclinical development, or diagnostics. In this phase most of the Group's customers are both curious and willing to test new concepts and analytical methods to address the clear needs and challenges related to understanding, identifying and analyzing biopharmaceuticals. More and more of Genovis' customers in the biopharma industry are now using the products farther along in the value chain for biological drug development and have growing confidence in Genovis as a provider of high-quality, innovative products for the biopharma industry. A key component of Genovis' growth strategy is to continue to launch innovative products as the brand grows stronger and in pace with the expansion and broadening of our customer base.

Financial overview

Sales revenue, 12-month rolling (2018 – 2021)




Net sales

Consolidated net sales for the fourth quarter totaled SEK 42,060 (19,850) thousand, an increase in sales of 112%. About SEK 20 million relates to licensing agreements with Selecta Bioscience through the newly signed agreement, corresponding to 2/3 of the payment that Genovis has received. The remaining undertaking amounts to approximately 1/3 and has been recognized as deferred revenue. Growth is 108%, adjusted for currency effects.

Consolidated net sales for the full year rose to SEK 93,018 (61,030) thousand, representing an increase in sales of SEK 31,988 thousand and corresponding to 52%. Growth is 56%, adjusted for currency effects.

Sales by quarter 2018 – 2021




Operating profit before depreciation and amortization (EBITDA)

For the fourth quarter, operating profit before depreciation and amortization was SEK 23,361 (6,196) thousand, corresponding to an increase of SEK 17,164 thousand, largely attributable to the revenue from Selecta Bioscience. For the full year, operating profit before depreciation and amortization totaled SEK 30,314 (8,573) thousand, corresponding to an increase of SEK 21,741 thousand.

Operating profit (EBIT)

For the fourth quarter, operating profit after depreciation and amortization was SEK 21,895 (4,604) thousand, corresponding to an increase of SEK 17,291 thousand, largely attributable to the revenue from Selecta Bioscience. For the full year, operating profit after depreciation and amortization totaled SEK 24,543 (3,140) thousand, corresponding to an increase of SEK 21,403 thousand.

Operating profit (EBIT) rolling 12 months



Comprehensive income

Comprehensive income for the fourth quarter was SEK 23,175 (6,347) thousand, which corresponds to an increase of SEK 16,828 thousand. Earnings per share, based on a weighted average of the number of outstanding shares, totaled SEK 0.35 (0.10).

For the full year, comprehensive income totaled SEK 26,828 (1,973) thousand, corresponding to an increase of SEK 24,856 thousand. Earnings per share, based on a weighted average of the number of outstanding shares, totaled SEK 0.41 (0.03).

Costs

Consolidated expenses for the fourth quarter totaled SEK 20,523 (16,639) thousand. Expenses are allocated as follows: raw materials and consumables SEK 3,394 (1,482) thousand, personnel costs SEK 7,553 (8,170) thousand, other external expenses SEK 6,698 (4,917) thousand and other

operating expenses 1,412 (478) thousand. Depreciation and amortization for the quarter amounted to SEK 1,466 (1,592) thousand.

For the full year, expenses totaled SEK 71,709 (62,506) thousand. Expenses are allocated as follows: raw materials and consumables SEK 10,652 (6,276) thousand, personnel costs SEK 30,883 (28,653) thousand, other external expenses

SEK 21,966 (18,657) thousand and other operating expenses 2,437 (3,487) thousand. Depreciation and amortization for the period increased by SEK 338 to SEK 5,771 (5,433) thousand.

Investments

The Group's net capital expenditure in the fourth quarter was SEK 313 (249) thousand, including SEK 127 (237) thousand attributable to property, plant, and equipment (mainly laboratory equipment), and SEK 186 (12) thousand relating to investments in intangible assets.

For the full year, net capital expenditure totaled SEK 4,491 (20,431) thousand, including SEK 1,773 (1,433) thousand attributable to property, plant, and equipment, primarily laboratory equipment.

Investments in intangible assets and financial assets totaled SEK 2,718 (18,998) thousand, of which SEK 1,052 thousand relates to patents and SEK 1,666 thousand relates to a deferred purchase consideration for QED, which was acquired in 2020. The investment in the previous year largely related to the acquisition of QED.

Cash flow and financial position

Total shareholders' equity for the Group was SEK 113,994 (87,165) thousand after taking the result for the period into account. Equity per share based on the weighted average of the number of outstanding shares (basic and diluted) at the end of the period was SEK 1.74 (1.34).

The Group's equity ratio at the end of the period was 80% (82).

Consolidated cash flow for fourth quarter totaled SEK 36,105 (-2,113) thousand. The improvement in cash flow comes from the payment under the licensing agreement with Selecta Bioscience. Cash flow from financing activities totaled SEK -950 (-1,192) thousand.

For the full year, consolidated cash flow was SEK 37,197 (29,126) thousand. Cash flow from financing activities totaled SEK -3,722 (49,572) thousand.

Consolidated cash and cash equivalents at the end of the period amounted to SEK 81,315 (44,118) thousand. Taking expected revenue into account, the Board believes that the existing working capital is sufficient to run the Company over the next twelve months.

Only the Group has interest-bearing liabilities; they relate in their entirety to the present value of estimated future lease payments, which also includes rent for premises.

Lease liabilities (SEK thousand)

Non-current lease liabilities

Maturity between 1 and 4 years	1,123
--------------------------------	-------

Current lease liabilities

Maturity within 1 year	1,708
------------------------	-------

Taxes

The Group has a deferred tax asset of SEK 6,741 (6,173) thousand, of which SEK 1,718 (1,718) arises from the Parent Company, and the remainder relates to deferred tax on intra-group profit on inventories of SEK 5,023 (4,455) thousand. It is the Board's assessment that future taxable surpluses will be available against which the unutilized tax losses can be utilized.

Employees

On December 31, 2021, the Group employed 33 people. In all, 27 people are employed by the Parent Company in Lund and six people work for the subsidiary Genovis Inc. in the US.

Share capital and share performance

Share capital at the end of the quarter was SEK 16,366,428 and the total number of shares was 65,465,714 with a par value of SEK 0.25.

Genovis shares are traded on Nasdaq First North Growth Market under the ticker symbol GENO. First North is Nasdaq's European emerging market intended for growth companies.

Certified Adviser

Erik Penser Bank, +46 (0)8 463 83 00, certifiedadviser@penser.se.

Parent Company

Net sales and operating profit/loss in the Parent Company are attributable to the primary and only business area: sales of products and/or research-based innovations.

Revenue

Revenue for the fourth quarter, including change in inventory, finished goods, totaled SEK 37,625 (30,233) thousand, including SEK 36,475 (32,778) thousand attributable to sales, SEK -116 (-3,467) thousand relating to a change in inventory, finished goods, and SEK 1,266 (922) thousand in other revenue. Other revenue relates to foreign exchange gains and grants. About SEK 20 million relates to licensing agreements with Selecta Bioscience, which account for 2/3 of the obligations for 2021. The remainder is recognized in the balance sheet as deferred revenue.

For the full year, revenue totaled SEK 72,856 (61,860) thousand, including SEK 68,399 (61,182) thousand attributable to sales, 145 (-1,094) thousand relating to change in inventory, finished goods, and SEK 4,312 (1,772) thousand attributable to other revenue. Other revenue relates to foreign exchange gains and grants.

Costs

The Parent Company's expenses for the fourth quarter totaled SEK 13,999 (10,910) thousand. For the full year, expenses totaled SEK 46,826 (42,299) thousand.

Earnings

Profit for the fourth quarter was SEK 23,624 (19,187) thousand, while profit for the full year was SEK 26,237 (18,875) thousand.

Investments

Net capital expenditure in the fourth quarter was SEK 301 (312) thousand, including SEK 115 (300) thousand attributable to property, plant, and equipment (mainly laboratory equipment), and SEK 186 (12) thousand relating to investments in intangible assets.

For the full year, net capital expenditure totaled SEK 4,305 (22,178) thousand, including SEK 1,587 (1,433) thousand attributable to property, plant, and equipment, primarily laboratory equipment.

Investments in intangible assets and financial assets totaled SEK 2,718 (20,745) thousand, of which SEK 1,052 thousand relates to patents and SEK 1,666 thousand relates to a deferred purchase consideration for QED, which was acquired in 2020. The investment in the previous year largely related to the acquisition of QED.

Taxes

The Parent Company has a deferred tax asset and at the end of the period it amounted to SEK 1,718 (1,718) thousand, corresponding to a loss carryforward of SEK 8,340 thousand. It is the Board's assessment that future taxable surpluses will be available against which the unutilized tax losses can be utilized. The Company's total tax loss amounts to SEK 116 (143) million.

Subsidiary Genovis Inc.

The subsidiary Genovis Inc. handles all sales of SmartEnzymes™ in the North American market, as well as sells, produces and develops new antibodies for research, diagnostics and drug development. The Company also offers customized antibody services for academia and industry.

Other information

Events after the end of the year

No significant events were reported after the end of the year.

Related party transactions

Genovis' board member and principal owner Mikael Lönn, who holds a 15.26% stake in Genovis, owns 12.24% of the shares in Redeye AB, for which Mikael Lönn is also a board member. Genovis has purchased analysis services from Redeye AB for a total of SEK 420 thousand during the period.

Nomination Committee

Nomination Committee prior to the 2022 Annual General Meeting:

Mikael Lönn

Aktia Placeringsfonder, represented by Markus Lindqvist, Director, Aktia Fondbolag AB

TIN Ny Teknik, represented by Erik Sprinchorn, Portfolio manager

Second AP Fund, represented by Johan Sjöström, Portfolio manager

Proposals for Nomination Committee

Shareholders wishing to submit comments or proposals to the Nomination Committee should do so no later than March 1, 2022. Send proposals to the following addresses:

Genovis AB, Investor Relations, Box 790, 220 07 Lund

Email: legal@genovis.com

Outlook

Although the Life Science field is relatively independent of business cycles, periods of uncertainty can influence our customers' appetite to invest in new technology. With most development projects proceeding according to plan, Genovis is positioned to make additional advances with respect to both new products and sales in 2022. The COVID-19 outbreak has had a significant impact on the current business climate, but despite the uncertainty found in short-term market trends, Genovis' growth potential for the future remains intact.

Risk Factors

Genovis' general view of the financial risks that could affect operations has not changed since the description published in the most recent annual report. Genovis' business risks include the risk that anticipated revenue might not materialize since the Company is active in a market in which competing companies have substantially larger financial resources at their disposal. For a detailed overview of the Company's financial risks, please refer to page 59 in Genovis' 2020 Annual Report.

Annual Report

The 2021 Annual Report will be published on the Genovis website www.genovis.com and will be available at the Genovis office as of April 21, 2022.

2022 Annual General Meeting

The Annual General Meeting will be held on Thursday, May 12, 2022; time and place will be announced at a later date.

Financial calendar

Annual Report	April 21, 2022
Interim Report January 1 – March 31, 2022	April 27, 2022
Annual General Meeting	May 12, 2022
Half-Yearly Report January 1 – June 30, 2022	August 12, 2022
Interim report January 1 – September 30, 2022	November 15, 2022
Interim report January 1 – December 31, 2022	February 15, 2022

Reports may be downloaded at the Genovis website:

<https://investor.genovis.com/en/financial-reports/> or requested from the company by phone or letter:
Genovis AB, Box 790, 220 07 Lund Tel.: +46 (0)46-10 12 30

Forward-looking information

This report contains forward-looking information based on the current expectations of Group management at Genovis. Although the management believes that the expectations reflected in such forward-looking information are reasonable, no assurance can be given that such expectations will prove correct. Consequently, actual future results may vary materially from those implied in the forward-looking statements due to such changes in economic, market and competitive conditions, changes in the regulatory environment and other government actions, fluctuations in exchange rates and other factors.

Accounting policies

This interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting and the relevant provisions of the Swedish Annual Accounts Act. The report for the Parent Company has been prepared in accordance with chapter 9 of the Swedish Annual Accounts Act, Interim Reports. The accounting policies applied for the Group and the Parent Company are consistent with the accounting policies used in the preparation of the most recent annual report.

Financial information - Group

Statement of comprehensive income

(SEK 000s)	Oct.-Dec.		Jan.-Dec.	
	2021	2020	2021	2020
Net sales	42,060	19,850	93,018	61,030
Change in inventory, finished goods	-99	471	-1,077	2,844
Other operating income/expenses*	457	922	4,311	1,772
Raw material and consumables	-3,394	-1,482	-10,652	-6,276
Gross profit	39,024	19,761	85,600	59,370
Personnel costs	-7,553	-8,170	-30,883	-28,653
Other external costs	-6,698	-4,917	-21,966	-18,657
Other operating costs	-1,412	-478	-2,437	-3,487
Operating profit before depreciation and amortization (EBITDA)	23,361	6,196	30,314	8,573
Depreciation, amortization, and impairment of plant, property, and equipment and intangible assets	-1,466	-1,592	-5,771	-5,433
Operating profit (EBIT)	21,895	4,604	24,543	3,140
Net financial items	-61	-230	60	-991
Profit after financial items	21,834	4,374	24,603	2,149
Taxes	373	4,296	174	4,297
Profit after tax for the period	22,207	8,670	24,777	6,446
Items that may be reclassified subsequently to profit or loss				
Translation of foreign subsidiary	968	-2,323	2,051	-4,473
Comprehensive income for the period**	23,175	6,347	26,828	1,973

* The item Other operating income/expenses relates to exchange rate fluctuations.

**The entire profit is attributable to Parent Company shareholders

	Oct.-Dec.		Jan.-Dec.	
	2021	2020	2021	2020
Earnings per share (SEK)*	0.35	0.10	0.41	0.03
Number of shares				
Weighted average for the period	65,465,714	65,465,714	65,465,714	65,090,819
Number of shares at start of period	65,465,714	65,465,714	65,465,714	63,100,000
Number of shares at end of period	65,465,714	65,465,714	65,465,714	65,465,714
Share price at end of period, SEK	73.0	31.5	73.0	31.5

* Based on weighted average of the number of outstanding shares (basic and diluted)

Summary Balance Sheet

(SEK 000s)	Dec. 31 2021	Dec. 31 2020
Assets		
<i>Non-current assets</i>		
Intangible assets	16,476	15,832
Property, plant and equipment	9,604	12,497
Financial assets	6,818	6,243
<i>Current assets</i>		
Current assets	27,537	27,958
Cash and cash equivalents	81,315	44,118
Total assets	141,750	106,648
Equity and liabilities		
Equity	113,994	87,165
Deferred tax	2,387	2,421
Noncurrent liabilities	1,123	3,318
Current liabilities	24,246	13,744
Total equity and liabilities	141,750	106,648

Changes in equity

(SEK 000s)	Dec. 31 2021	Dec. 31 2020
Opening balance	87,165	35,620
Rights issue	0	49,571
Exchange rate difference	2,051	-4,472
Profit for the period	24,778	6,446
Amount at end of period	113,994	87,165
Attributable to shareholders in Genovis AB	113,994	87,165

Key financial figures	Dec. 31 2021	Dec. 31 2020
Equity/assets ratio (%)	80	82
Equity per share at end of period* (SEK)	1.74	1.34

* Based on weighted average of the number of outstanding shares (basic and diluted).

Summary Statement of Cash Flows

(SEK 000s)	Oct.-Dec.		Jan.-Dec.	
	2021	2020	2021	2020
Operating profit for the period	21,895	4,604	24,543	3,140
Adjustment for items not affecting cash flow	1,466	1,592	5,771	5,433
Changes in working capital	13,694	-6,638	15,074	-3,827
Net financial items	313	-230	23	-991
Cash flow from operating activities	37,368	-672	45,411	3,755
Investing activities	-313	-249	-4,491	-20,431
Cash flow after investing activities	37,055	-921	40,920	-16,676
Financing activities	-950	-1,192	-3,723	-3,770
Rights issue	0	0	0	49,572
Cash flow for the period	36,105	-2,113	37,197	29,126
Cash and cash equivalents at start of period	45,210	46,231	44,118	14,992
Cash and cash equivalents at end of period	81,315	44,118	81,315	44,118

Financial information – Parent Company

Summary Income Statement

(SEK 000s)	Oct.-Dec.		Jan.-Dec.	
	2021	2020	2021	2020
Operating income incl. change in inventory, finished goods	37,625	30,233	72,856	61,860
Operating expenses	-13,999	-10,910	-46,826	-42,299
Operating profit	23,626	19,323	26,030	19,561
Net financial items	-2	-136	207	-686
Profit for the period	23,624	19,187	26,237	18,875

Summary Balance Sheet

(SEK 000s)	Dec. 31 2021	Dec. 31 2020
Assets		
Non-current assets	31,687	30,861
Current assets	40,378	41,954
Cash and cash equivalents	77,973	38,884
Total assets	150,038	111,699

(SEK 000s)	Dec. 31 2021	Dec. 31 2020
Equity and liabilities		
Restricted equity	16,366	16,366
Unrestricted equity	112,972	86,735
Liabilities		
Current liabilities	20,700	8,598
Total equity and liabilities	150,038	111,699

Changes in equity

(SEK 000s)	Dec. 31 2021	Dec. 31 2020
Opening balance	103,101	34,654
Rights issue	0	49,571
Profit for the period	26,237	18,876
Equity at the end of the period	129,338	103,101

Summary Statement of Cash Flows

(SEK 000s)	Oct.-Dec.		Jan.-Dec.	
	2021	2020	2021	2020
Operating profit for the period	23,625	19,323	26,030	19,561
Adjustment for items not affecting cash flow	401	344	1,596	1,279
Changes in working capital	12,859	-22,578	15,561	-23,030
Net financial items	-1	0	207	-1
Cash flow from operating activities	36,884	-2,911	43,394	-2,191
Investing activities	-301	-312	-4,305	-22,178
Cash flow after investing activities	36,583	-3,223	39,089	-24,369
Financing activities	-	0	-	49,572
Cash flow for the period	36,583	-3,223	39,089	25,203
Cash and cash equivalents at start of period	41,390	42,107	38,884	13,681
Cash and cash equivalents at end of period	77,973	38,884	77,973	38,884

Auditor's review

This report has not been reviewed by the Company's auditor.

Statement by the Board of Directors and Chief Executive Officer

The Board of Directors and the Chief Executive Officer certify that this interim report provides a true and fair overview of the development of the Parent Company's and the Group's business activities, financial position and results of operations as well as the significant risks and uncertainties to which the Parent Company and the companies included in the Group are exposed.

Lund February 8, 2022
Genovis AB (publ.)

On behalf of the Board of Directors Fredrik Olsson
Chief Executive Officer

For more information

Additional information about the company is available on its website: [genovis.com](https://www.genovis.com)
For questions about this report, please contact: Fredrik Olsson, CEO, and President,
Tel.: +46 (0)702-276 46 56.

This information is information that Genovis AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on February 8, 2022.

This information is also available in Swedish. Please visit: <https://investor.genovis.com/en/>